Xcout Intel
Excalipoint
Excalipoint Therapeutics is a clinical-stage biotechnology company headquartered in Shanghai, China. The firm is dedicated to developing next-generation T-cell engager (TCE) therapies and unlocking the therapeutic potential of T-cell based treatments.
Subscribe to see Excalipoint’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Excalipoint at a glance
Excalipoint is a biotech company headquartered in China. Its most recent funding round, Seed, raised $68.7M in March 2026. Xcout tracks 1 named person at Excalipoint, including Lei Fang (co-founder, chairman, and CEO).
Excalipoint leadership
- Lei Fangco-founder, chairman, and CEO
Excalipoint funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Seed | $68.7M | 4 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Excalipoint competitors
A few of Excalipoint's closest competitors — see the full list of competitors and alternatives →
ImmuXell Biotechnology is a clinical-stage biopharmaceutical innovation company headquartered in Shanghai, China. Founded in 2021, the company focuses on developing novel immune cell therapies targeted at treating solid tumor cancers.
Eureka Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing transformative technology platforms and first-in-class T-cell therapies to access cancer-specific targets.
Allink Biotherapeutics is a clinical-stage biotechnology company founded in 2023 and based in Shanghai, China, focused on developing advanced antibody-drug conjugates (ADCs) and therapeutics.
Carcell Biopharma Inc. is an EVX company that develops next-generation cell and gene therapies utilizing a "platform of platforms" model. Based in both Singapore and Shanghai, the company focuses on advancing innovative treatments in the biotechnology sector.
Lyvgen Biopharma is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immune-oncology therapies. Founded in 2016, the company maintains its headquarters in Shanghai, China, alongside research facilities in Suzhou.
Tiankeya (also known as Beijing TCR Cure Biopharma Technology Co., Ltd.) is a clinical-stage biopharmaceutical company founded in 2016 and headquartered in China, with operations in China and the United States. The company focuses on the innovation, development, and clinical translation of engineered T cell and immune cell therapies to treat cancer and solid tumors.
Get Excalipoint's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Excalipoint in Xcout Intel
- 1 named person with titles, LinkedIn and board committees
- 1 funding round with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access